FOURIER

Further Cardiovascular Outcomes Research with PCSK9 Inhibition

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.

27 564

Schéma

Double-blind RCT, median 2.2 yr

Critère

Composite CV events

Pertinence

Résultat9.8% vs 11.3% (HR 0.85, 95% CI 0.79-0.92, p<0.001). Median LDL 30 mg/dL.

Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722. 10.1056/NEJMoa1615664

Discussion et critique

Short follow-up may underestimate effect — extended follow-up suggests larger benefit over time. Cost-effectiveness limits broad uptake; reserved for highest-risk patients.